⚕ GalenOps field
←

SITE005-0150

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE005 (FRA) · Dr. Muller
consented 2022-08-21

AEs
6
Serious
1
Dropout signal
–

Adverse events

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-09-13 (study day 7); relationship: not assessed

severe serious assessed

Grade 3 Alopecia — outcome: RECOVERED/RESOLVED; onset 2022-09-17 (study day 11); relationship: N; serious criteria: hospitalization

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2022-09-25 (study day 19); relationship: not assessed

moderate assessed

Grade 2 Anaemia — outcome: RECOVERED/RESOLVED; onset 2022-10-13 (study day 37); relationship: N

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2022-11-04 (study day 59); relationship: not assessed

mild assessed

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2022-11-09 (study day 64); relationship: not assessed

Data queries

No data queries.